Angiotensin: Physiology and What Research Reports

What Is Angiotensin?

Angiotensin is not one molecule but a family of short peptide hormones generated by the stepwise cleavage of a liver-derived protein called angiotensinogen. The enzyme renin, released from the kidney, cuts angiotensinogen to angiotensin I; angiotensin-converting enzyme (ACE) then trims angiotensin I to the eight-amino-acid peptide angiotensin II, the most intensively studied member of the group. Further peptidases produce angiotensin III, angiotensin IV and angiotensin-(1-7). Together these peptides, their enzymes and their receptors form the renin-angiotensin system (RAS).

Because every member of the family is a peptide, angiotensin is a standard reference point in peptide physiology: it illustrates how one precursor protein can yield several signalling molecules with different, sometimes opposing, receptor targets.

The angiotensin peptide family at a glance

Where Angiotensin Is Produced and What It Does

Angiotensinogen comes mainly from the liver, renin from the juxtaglomerular cells of the kidney, and ACE from vascular endothelium, with the pulmonary circulation historically treated as a major conversion site. A counter-regulatory enzyme, ACE2, diverts the pathway toward angiotensin-(1-7). Researchers reported that ACE2 acted through the renin-angiotensin system to alleviate liver fibrosis in that experimental setting (PMID 38463024). Separately, a 2020 study reported that ACE2 expression in the lung was not induced by renin-angiotensin system components (PMID 33043048).

The classical actions of angiotensin II are vasoconstriction, stimulation of aldosterone release, sodium and water retention, and sympathetic activation. Its vasoconstrictor action is the basis for its clinical study in shock states, where a review described angiotensin II as a vasopressor option in vasodilatory shock (PMID 30784606). A 2024 review of real-life use summarised published experience and literature on angiotensin II in that clinical context (PMID 39336524).

Signalling beyond the cell surface

Angiotensin II is usually described as acting on membrane AT1 and AT2 receptors, but a review also reported that angiotensin II can act at intracellular sites in cardiac, vascular and renal tissue, not only at surface receptors (PMID 29351452). That intracellular pool is one reason researchers distinguish between circulating angiotensin concentrations and locally generated tissue angiotensin.

Angiotensin, Fibrosis and Kidney Cells

Beyond haemodynamics, angiotensin II is studied as a driver of tissue remodelling. A review examined modulation of angiotensin II signalling in the prevention of fibrosis across organ systems (PMID 25949522). In the liver, the ACE2 arm of the system was reported to alleviate fibrosis in an experimental model (PMID 38463024).

At the cellular level, a 2023 study reported that angiotensin II upregulated NADH/NADPH oxidase 4 and induced podocyte apoptosis, linking angiotensin signalling to oxidative stress in kidney filtration cells (PMID 37037482). These mechanistic findings are laboratory observations and are not statements about outcomes in people.

How Angiotensin Is Measured and Studied

Angiotensin peptides are short-lived and present at very low concentrations, so measurement is technically demanding. Common approaches include plasma renin activity assays, immunoassays for individual peptides, and mass-spectrometry-based angiotensin profiling that quantifies several family members at once. The difficulty of this work is illustrated by a 2024 analysis that critically evaluated whether angiotensin-(1-12) could be detected in humans, rats and mice (PMID 38716648).

Physiological states shift the balance between arms of the system. Researchers tracked the dynamics of renin, angiotensin II and angiotensin-(1-7) during pregnancy in relation to predisposition to hypertension-associated complications (PMID 30123953). Animal and invertebrate models are also used to probe conserved functions, such as the report that angiotensin II and angiotensin III regulated water flow through aquaporins in a clam worm (PMID 16041122).

Where the Term Appears in Medicine

Two very different clinical uses keep angiotensin in circulation as a term. First, the peptide itself: reviews have described synthetic human angiotensin II as a vasopressor studied in vasodilatory shock (PMID 30784606), and a 2024 review compiled real-life use alongside the published literature (PMID 39336524).

Second, drugs that block the pathway. Angiotensin II receptor blockers (ARBs) antagonise the AT1 receptor and are a recognised class in hypertension and related cardiovascular conditions, as described in a clinical review of the class (PMID 30725712). An earlier review examined the role of the angiotensin II receptor blocker valsartan in heart failure (PMID 20428262). Readers encountering "angiotensin" in a medication list are usually meeting a blocker of the system rather than the peptide itself.

Angiotensin Safety Signals: What Studies Report

Angiotensin II given as a vasopressor is a hospital-administered agent, and the reviews that describe it also discuss monitoring and reported safety considerations in critically ill patients (PMID 39336524); an earlier review framed the same trade-offs in vasodilatory shock (PMID 30784606). For the blocking drugs, a clinical review of angiotensin II receptor blockers set out the class adverse-effect profile and contraindications, including cautions relevant to pregnancy (PMID 30725712).

On the mechanistic side, findings such as angiotensin II-induced podocyte apoptosis through NADH/NADPH oxidase 4 are reported as cell-level injury signals rather than clinical adverse events (PMID 37037482). This page is for educational purposes only and is not medical advice; consult a licensed physician about any medication, symptom or health decision.

Why Angiotensin Matters in Peptide Education

• It shows how a single precursor yields multiple peptides with distinct receptors and, in the ACE2/angiotensin-(1-7) arm, partly opposing effects (PMID 38463024).
• It demonstrates that peptide signalling is not limited to cell-surface receptors, as reviewed for intracellular angiotensin II (PMID 29351452).
• It illustrates how analytical uncertainty shapes conclusions, as in the critical evaluation of angiotensin-(1-12) (PMID 38716648).
• It connects peptide biology to widely prescribed medicines, since ARBs act on the same receptor the peptide uses (PMID 30725712).

References

• Angiotensin II Receptor Blockers (ARB) (StatPearls)
• Angiotensin-converting enzyme 2 alleviates liver fibrosis through the renin-angiotensin system (World Journal of Gastroenterology, 2024)
• Angiotensin II in Vasodilatory Shock (Critical Care Clinics, 2019)
• Modulation of angiotensin II signaling in the prevention of fibrosis (Fibrogenesis & Tissue Repair, 2015)
• Angiotensin-(1-12): Does It Exist? A Critical Evaluation in Humans, Rats, and Mice (Hypertension, 2024)
• Angiotensin II-Real-Life Use and Literature Review (Medicina, 2024)
• Role of intracellular angiotensin II (American Journal of Physiology. Heart and Circulatory Physiology, 2018)
• Upregulation of NADH/NADPH oxidase 4 by angiotensin II induces podocyte apoptosis (Kidney Research and Clinical Practice, 2023)
• Dynamics of Renin, Angiotensin II, and Angiotensin (1-7) during Pregnancy and Predisposition to Hypertension-Associated Complications (Bulletin of Experimental Biology and Medicine, 2018)
• Role of the angiotensin II receptor blocker valsartan in heart failure (Experimental and Clinical Cardiology, 2001)
• Angiotensin III as well as angiotensin II regulates water flow through aquaporins in a clam worm (Bioscience, Biotechnology, and Biochemistry, 2005)
• Angiotensin-converting enzyme 2 expression is not induced by the renin-angiotensin system in the lung (ERJ Open Research, 2020)